Wednesday 24 May 2017

Irish Supreme Court rules on litigation funding ban

The Supreme Court of Ireland has ruled that the doctrines of champerty and maintenance prevented third party litigation funders from financing litigation.
The ruling concerns a non-competition case where Persona Digital Telephony and Sigma Wireless Networks were suing the Business Minister after they lost a bid in a mobile telephone auction.
The Supreme Court upheld a ruling of the Irish High Court that the funding agreement with Harbour Capital was unlawful.  The Supreme Court president found that the fund had no connection with the claimants other than the funding arrangements.  As such, it was a “champertous agreement” which, in the absence of a statutory exception, was unlawful.
The judgment comes at a time when claimants are considering antitrust litigation in a number of jurisdictions.  It remains to be seen what effect the ruling will have on the attractiveness of Ireland as a venue for such actions. 
It might be said that the ruling does no more than confirm the existing position on funding based on a narrow construction of existing statutory provisions.  In this respect it is noteworthy that the president gave a nod to the need for legislation on the matter noting that such a complex and multi-faceted issue was “more suited to a legislative analysis”.

Persona Digital Telephony Limited & Sigma Wireless Networks Limited v The Minister for Public Enterprise, Ireland and the Attorney General [2017] IESC 27

Wednesday 17 May 2017

Commission opens rare abuse of dominance case into excessive pricing by Aspen Pharma

Commission opens rare abuse of dominance case into excessive pricing by Aspen Pharma

The European Commission has opened an investigation into whether Aspen Pharma is charging excessive prices for certain cancer medicines in breach of Article 102 TFEU.
The Commission suspects that Aspen has imposed “very significant” and “unjustified” price increases of up to several hundred per cent for medicines that it acquired after the expiry of patent protection.
The Commission’s investigation will cover the whole of the EEA except Italy.  In 2016 the Italian competition regulator fined Aspen EUR 5.2 million for infringing Article 102 TFEU as a result of unfair pricing and found price increases of up to 1500 per cent for some cancer medicines.
This is the first competition investigation by the Commission into excess pricing in the pharmaceutical sector.  Excessive pricing cases are rare in EU law and the competition authorities cite the mantra that they do not want to act as price regulators.  It may be that by opening this case, the Commission is seeking to achieve a uniform approach at national and EU level to what can be a knotty legal and economic question: the circumstances in which prices may be deemed excessive.
Commission press release. IP/17/1323.